The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network. NCCN colon cancer practice guidelines v.3.2005. Available at: www.nccn.org. Accessed on June 1, 2005.
2.
GoldsteinD., MitchellP., MichaelM.Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.Br J Cancer.2005; 92: 832–837.
3.
TournigandC., AndreT., AchilleE.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol.2004; 22: 229–237.
4.
DucreuxM., AdenisA., BennounaJ.Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from an interim safety analysis. Abstract 3596 presented at: 2005 ASCO Annual Meeting; May 14-17, 2005. Orlando, Fl.
5.
Maindrault-GoebelF., LouvetC., AndreT.Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6).Eur J Cancer.1999; 35: 1338–1342.
6.
De GramontA., CervantesA., AndreT.OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer.J Clin Oncol.2005; 22(suppl 3525): 1209–1214.
7.
TaiebJ., ArtruP., PayeF.Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.J Clin Oncol.2005; 23: 502–509.
8.
de GramontA., TournigandC., LouvetC.Oxaliplatin, folinic acid, and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD.Rev Med Interne.1997; 18: 769–775.
9.
de GramontA., FigerA., SeymourM.Leucovorin and fluorouracil with and without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol.2000; 18: 2938–2947.
10.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines v.1.2005. Available at: www.nccn.org. Accessed on June 1, 2005.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–109.
AndreT., BoniC., Mounedji-BoudiafL.Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.N Engl J Med.2004; 350: 2343–2351.
14.
BrandiG., PantaleoM.A., GalliC.Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer.2003; 89: 477–481.
15.
QureshiK.M., LeichmanC., BerdzikJ.Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization.Proc Am Soc Clin Oncol.2003; 22: 789 (abstract 3173).
16.
DoldF., HoeyD., CarberryM.Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin.Proc Am Soc Clin Oncol.2002 (abstract 1478).
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective.Semin Oncol.2003; 30(suppl 13): 10–17.
19.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–3585.
20.
KretzschmarA., Thuss-PatienceP.C., PinkD.Extravasations (E) of oxaliplatin (O).Proc Am Soc Clin Oncol.2002 (abstract 2900).
21.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea.J Clin Oncol.2004; 22: 2918–2926.
22.
GamelinE., GamelinL., BossiL.Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.Semin Oncol.2002; 29(suppl 15): 21–33.
23.
GamelinL., Boisdron-CelleM., DelvaR.Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer.Clin Cancer Res.2004; 10: 4055–4061.
24.
TakimotoC.H., RemickS.C., SharmaS.Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute organ dysfunction working group study.J Clin Oncol.2003; 21: 2664–2672.
25.
DoroshowJ.H., SynoldT.W., GandaraD.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.Semin Oncol.2003; 30(suppl 15): 14–19.
26.
Rubbia-BrandtL., AudardV., SartorettiP.Severe hepatic sinsuoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Ann Oncol.2004; 15: 460–466.
27.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–989.
